Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Malladi Drugs

Request full access

Pharmaceutical manufacturing company manufacturing medicines

Chennai, IndiaFounded 1999Biotech & Life Sciences

About Malladi Drugs

Malladi Drugs & Pharmaceuticals Ltd. is an established manufacturer of Active Pharmaceutical Ingredients (APIs) based in India, with a significant global footprint. Founded in 1980 by the late Mr. M L N Sastry, a microbiologist with deep expertise in fermentation technology, the company pioneered the manufacturing of Ephedrine and Pseudoephedrine salts in India through a fully indigenous process. This early focus on bi-synthetic processes established the firm's knowledge-driven approach.

The company's core business involves the development and distribution of APIs, with a primary focus on the cough and cold therapeutic segment. Over the years, Malladi has expanded its portfolio to include other key areas such as anti-histamines, anti-convulsants, anti-depressants, and anxiolytics. Its business model is centered on supplying these APIs to large pharmaceutical companies globally, with exports to over 60 countries accounting for more than 85% of its revenue. A key strategic partnership exists with Bayer AG, for whom Malladi exclusively produces certain products. In addition to API sales, the company generates revenue through contract manufacturing, custom synthesis, and contract research services, supporting clients from clinical research to large-scale production.

Malladi operates three cGMP manufacturing facilities in India—two in Ranipet, Tamil Nadu, and one in Renigunta, Andhra Pradesh—which have been inspected and approved by numerous international regulatory agencies, including the US FDA, EDQM (Europe), and TGA (Australia). The company also operates a state-of-the-art R&D center near Chennai, which is a recognized center for doctoral programs. A significant milestone was the acquisition of Novus Fine Chemicals in New Jersey, USA, making it the first Indian company to acquire an API manufacturing facility outside of India. The company recently raised INR 2,500 million from the India Life Sciences Fund to facilitate capacity expansion and the launch of new molecules.

Source: Dealroom company data

Malladi Drugs in the Chennai ecosystem

Live from Dealroom

The Malladi Drugs office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later1 investor entered at this stage

  • Invascent
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇮🇳 India99.7%
🇰🇭 Cambodia0.3%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Malladi Drugs on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Malladi Drugs on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.